Left Ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST)

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Mostovaya, Ira M ^a   Bots, Michiel L ^a   Van Den Dorpel, Marinus A ^b   Goldschmeding, Roel ^a   Den Hoedt, Claire H ^a,b   Kamp, Otto ^c   Levesque, Renée ^d   Mazairac, Albert H A ^a   Penne, E Lars ^a,c   Swinkels, Dorine W ^e   Van Der Weerd, Neelke C ^a,c   Ter Wee, Piet M ^c,f   Nubé, Menso J ^c,f   Blankestijn, Peter J ^a   Grooteman, Muriel P C ^c,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MONTREAL   (Canada)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; HEPCIDIN 25; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; END STAGE RENAL DISEASE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; RENAL REPLACEMENT THERAPY; SUDDEN DEATH; SURVIVAL RATE;

AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL DIALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 84895536306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084587     Document Type: Article

References (41)

1. Glassock RJ, Pecoits-Filho R, Barberato SH (2009) Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4 Suppl 1: S79-S91.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, et al (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192.
3. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, et al. (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65: 1492-1498. (Pubitemid 38406992)
4. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, et al. (2001) Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767. (Pubitemid 33115424)
5. Panichi V, Migliori M, De PS, Taccola D, Bianchi AM, et al. (2000) C-reactive protein as a marker of chronic inflammation in uremic patients. Blood Purif 18: 183-190. (Pubitemid 30619957)
6. Mora S, Musunuru K, Blumenthal RS (2009) The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 55: 219-228.
7. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR (2010) Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 70: 421-427.
8. Cottone S, Nardi E, Mule G, Vadala A, Lorito MC, et al. (2007) Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 67: 209-216. (Pubitemid 46605370)
9. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15: 43-58. (Pubitemid 32061655)
10. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772. (Pubitemid 30213096)
11. Biasillo G, Leo M, Della BR, Biasucci LM (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 5: 225-233.
12. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, et al. (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107: 1486-1491. (Pubitemid 36378485)
13. Kaneko K, Kanda T, Yokoyama T, Nakazato Y, Iwasaki T, et al. (1997) Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol 97: 3-12. (Pubitemid 27362624)
14. Ayerden EF, Ebinc H, Derici U, Aral A, Aybay C, et al. (2009) The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol 22:216-223.
15. Clarkson MR, Gupta S, Murphy M, Martin F, Godson C, et al. (1999) Connective tissue growth factor: a potential stimulus for glomerulosclerosis and tubulointerstitial fibrosis in progressive renal disease. Curr Opin Nephrol Hypertens 8: 543-548. (Pubitemid 30010391)
16. Zhang J, Chang L, Chen C, Zhang M, Luo Y, et al. (2011) Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res 91: 90-98.
17. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, et al. (2008) Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 370: 274-278.
18. Gerritsen KG, Peters HP, Nguyen TQ, Koeners MP, Wetzels JF, et al. (2010) Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. Am J Physiol Renal Physiol 298: F1457-F1464.
19. Fleming RE, Sly WS (2001) Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A 98: 8160-8162. (Pubitemid 32678004)
20. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, et al. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110: 1037-1044.
21. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, et al. (2013) Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 28: 3062-3071.
22. Nozari Y, Geraiely B (2011) Correlation between the serum levels of uric acid and HS-CRP with the occurrence of early systolic failure of left ventricle following acute myocardial infarction. Acta Med Iran 49: 531-535.
23. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, et al. (2008) Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 31: 2137-2146.
24. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, et al. (2005) Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 18: 47-51. (Pubitemid 40348276)
25. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, et al. (2010) Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 56: 1570-1579.
26. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, et al. (2012) Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 7: e39783.
27. Devereux RB, Casale PN, Hammond IW, Savage DD, Alderman MH, et al. (1987) Echocardiographic detection of pressure-overload left ventricular hypertrophy: effect of criteria and patient population. J Clin Hypertens 3: 66-78.
28. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, et al. (1989)Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367.
29. Greenland S, Finkle WD (1995) A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 142: 1255-1264. (Pubitemid 26006424)
30. Sjolander A (2009) Propensity scores and M-structures. Stat Med 28: 1416-1420.
31. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, et al. (2001) Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12: 2768-2774. (Pubitemid 33115425)
32. Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290. (Pubitemid 19202488)
33. Ritz E, Wanner C (2008) The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929.
34. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, et al. (2005) Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 67: 333-340. (Pubitemid 40019256)
35. Larsson O, Attman PO, Beckman-Suurkula M, Wallentin I, Wikstrand J (1986) Left ventricular function before and after kidney transplantation. A prospective study in patients with juvenile-onset diabetes mellitus. Eur Heart J 7: 779-791. (Pubitemid 16018797)
36. Guizar-Mendoza JM, mador-Licona N, Lozada EE, Rodriguez L, Gutierrez-Navarro M, et al. (2006) Left ventricular mass and heart sympathetic activity after renal transplantation in children and young adults. Pediatr Nephrol 21: 1413-1418.
37. Zoccali C, Mallamaci F, Tripepi G (2003) Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl : S105-S110. (Pubitemid 36605875)
38. Achinger SG, Ayus JC (2006) Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 17: S255-S261. (Pubitemid 44865258)
39. Nitta K, Akiba T, Uchida K, Otsubo S, Otsubo Y, et al. (2004) Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 27: 47-52. (Pubitemid 38208421)
40. Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, et al. (2012) Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98: 219-224.
41. Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324.